Biotech Values

[poorgradstudent]

TRVN:

I'm not trying to be controversial or anything. The totality of the preclinical and clinical data to date show that it works primarily in ways very similar to AT1R antagonists. In fact, much of the unique effects of TRV027 may actually end up being due to effects on renal function rather than on the heart. I just think the synopsis you copied did not accurately reflect the totality and likely cause of benefit. But that's just me.

I like the science here and am interested to see if it translates to the clinic.